Drug-biomarker co-development in oncology – 20 years and counting
Authors:
Open Access
- 1 January 2017
- journal article
- review article
- Published by Elsevier in Drug Resistance Updates
- Vol. 30, 48-62
Abstract
No abstract availableKeywords
This publication has 110 references indexed in Scilit:
- Temporal Resolution of Autophosphorylation for Normal and Oncogenic Forms of EGFR and Differential Effects of GefitinibBiochemistry, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancerHuman Pathology, 2010
- Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancersLung Cancer, 2007
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell, 2004
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003